Hospira (HSP) Relaunches Chemo Medication Oxaliplatin Injection; Generic Form of Eloxatin (SNY)
Tweet
Share
E-mailGet Alerts HSP Hot Sheet
Join SI Premium – FREE
Hospira, Inc. (NYSE: HSP), announced today the U.S. re-launch of oxaliplatin injection, Hospira's generic version of Sanofi's (NYSE: SNY) chemotherapy medication Eloxatin.
Sales of Eloxatin last year in the United States were approximately $1.5 billion.
Hospira originally launched oxaliplatin injection in August 2009 following a favorable ruling in patent litigation with Sanofi. Hospira settled the litigation with Sanofi in 2010 under an agreement which called for the eventual suspension of Hospira's sales at the end of June 2010, with the right to re-launch the product well in advance of patent expiry.
Oxaliplatin injection is a widely used oncology agent typically used to help treat colon and colorectal cancer. Hospira will initially offer oxaliplatin injection in 50 mg and 100 mg single-use vials. Hospira's oxaliplatin is a solution form of the product.
Sales of Eloxatin last year in the United States were approximately $1.5 billion.
Hospira originally launched oxaliplatin injection in August 2009 following a favorable ruling in patent litigation with Sanofi. Hospira settled the litigation with Sanofi in 2010 under an agreement which called for the eventual suspension of Hospira's sales at the end of June 2010, with the right to re-launch the product well in advance of patent expiry.
Oxaliplatin injection is a widely used oncology agent typically used to help treat colon and colorectal cancer. Hospira will initially offer oxaliplatin injection in 50 mg and 100 mg single-use vials. Hospira's oxaliplatin is a solution form of the product.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
- ChromaDex (CDXC) Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe
- Eaton (ETN) Awarded $26.6M in Federal Tax Credits
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
